Galapagos halts corporate separation, explores strategic alternatives; shares rise

Published 13/05/2025, 10:48
© Reuters.

Investing.com -- Galapagos (NASDAQ:GLPG) has put a halt to its previously announced corporate separation plans, opting instead to explore various strategic alternatives for its business units, including its cell therapy division. This decision comes in response to recent regulatory and market developments.

Shares in the company rose 3.5% in today’s Amsterdam trading session.

The company had initially announced the separation into two independent, publicly traded entities by mid-2025. These entities were to be Galapagos, with a focus on cell therapy, and SpinCo, a new biotech entity driven by business development (BD). However, this plan is now on hold as the Board of Directors re-evaluates strategic options across the portfolio.

In addition to these strategic changes, there has also been a leadership transition within the company. Henry Gosebruch, who was initially appointed as the CEO-designate of SpinCo, will now serve as the CEO of Galapagos. His responsibilities will include conducting the strategic evaluation and executing transformative business development transactions.

In conjunction with Gosebruch’s appointment, Jérôme Contamine, previously the Lead Non-Executive Director, has been named Chair of the Board of Directors. Meanwhile, Dr. Stoffels will continue to provide advisory support for the strategic review of the cell therapy pipeline.

With a strong balance sheet and available cash, the management is aiming to build an innovative pipeline. This suggests a shift from internal research and development to externally sourced assets.

The future of GLPG5101 and Galapagos’ decentralized manufacturing platform is also under active review. Possible outcomes for these aspects of the business include mergers, divestitures, or out-licensing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.